Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study
To assess the feasibility of a creative writing intervention in an advanced cancer population. Given it is a relatively simple intervention delivered by a non-clinician, the investigators are interested in better understanding its pattern of effect on patient psychological adjustment. The investigators aim to assess its feasibility in this study in order to inform a future larger study that will utilize a control arm.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 1 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Nov 19, 2018 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Interventions being studied
- Other: First Session; Other: Second Session; Behavioral: Third through Sixth Sessions
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. Participant must plan to receive follow up care at Dartmouth-Hitchcock. 2. Participant must have a lung or GI primary cancer diagnosed in the last 3 months. 3. Participant must have non-curable cancer as judged by the primary oncologist. 4. Participant must be comfortable conversing in English (reading and writing in English is not required). 5. Participant must be cognitively intact as judged by their responsible clinician. 6. Participant must have access to a working telephone and be willing and available to participate by this modality as needed. 7. Participants may be on anti-depressants and/or anxiolytics as long as the dosing has remained stable over the preceding 2 weeks.
1. Participant is expected to die in 6 months or less as judged by the responsible clinician. 2. Participant must not have already worked with the staff writer at Dartmouth Hitchcock prior to enrollment in this study. 3. Participant with an activated durable power of attorney for health care or cognitive impairment that interferes with ability to understand prognosis as determined by the primary oncologist. 4. Participant must not have uncontrolled physical symptoms.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 19, 2018. Always confirm current availability with the study team.